In 2020, the global peripheral vascular device market size was valued at $11.9 billion, with over 16 million yearly peripheral vascular procedures performed. The market size is expected to increase at a compound annual growth rate (CAGR) of 5.2% to reach $16.9 billion in 2026. Throughout this medical market research, we analyzed 113 peripheral vascular

In 2020, the European peripheral vascular device market size was valued at about €1.3 billion, with over 1.15 million peripheral vascular procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 2.9% to reach €1.6 billion in 2026. Throughout this medical market research, we analyzed 65

iData’s global atherectomy device market MedCore covers both the peripheral atherectomy market and the coronary atherectomy market. Medcores include a highly detailed and in-depth look at a segment in a market with all the associated sub- and sub-sub segments. iData MedCore reports allow users to delve deep into a specific market in order to obtain units sold, average selling prices (ASPs), market values, growth rates, a 10-year forecast including historical and future market estimates, and competitor market shares of any given market segment.

The full report suite on the U.S. market for peripheral vascular devices includes peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloon catheters, drug-coated balloons (DCBs), atherectomy devices, intravascular lithotripsy, chronic total occlusion (CTO) devices, surgical grafts, stent grafts, embolic protection devices (EPDs), peripheral thrombus management devices, inferior vena cava filters (IVCFs) and retrieval devices, carotid shunts, transcarotid arterial revascularization (TCAR) flow reversal systems and stents, diagnostic and interventional catheters, diagnostic and interventional guidewires, introducer sheaths, vascular closure devices (VCDs), transcatheter embolization devices and peripheral IVUS catheters.

The global peripheral chronic total occlusion (CTO) device market is expected to increase over the forecast period to reach $258.2 million by 2026. This global market research on chronic total occlusion (CTO) devices spans over 70 countries and includes re-canalization and re-entry devices, considered jointly in the analysis.

Atherectomy is a procedure used for removing plaque deposits from arteries. They have traditionally been more effective in peripheral than coronary applications. The success of atherectomies has been driven by the limited performance of existing treatments. Often a blockage is alleviated above the knee, only to have the blood flow deteriorate due to further bottlenecks below the knee. Failure to resolve these vascular limitations can result in critical limb ischemia, ulceration, limb pain or eventual amputation, if left untreated.

Chronic total occlusions (CTOs) are complete blockages of arteries. In the case of a hard plaque, over 50% of the occlusion could consist of calcified tissue. Soft plaques typically consist of cholesterol, macrophages and other cells.
The most common method to cross a CTO is to attempt to pass a guidewire through. In other cases, a specialty hydrophilic guidewire may be used. However, if these guidewire-based methods are not sufficient due to poor visualization and calcified heterogeneous lesions, specialized devices must come into play to enable the subsequent deployment of a stent, PTA balloon or even most atherectomy devices.

Atherectomy is a procedure used for removing plaque deposits from arteries. They have traditionally been more effective in peripheral than coronary applications. The success of atherectomies has been driven by the limited performance of existing treatments. Often, a blockage is alleviated above the knee, only to have the blood flow deteriorate due to further bottlenecks below the knee. Failure to resolve these vascular limitations can result in critical limb ischemia, ulceration, limb pain or eventual amputation if left untreated.